Form 8-K - Current report:
SEC Accession No. 0001104659-25-058888
Filing Date
2025-06-12
Accepted
2025-06-12 16:18:45
Documents
19
Period of Report
2025-06-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2517509d2_8k.htm   iXBRL 8-K 34498
2 EXHIBIT 4.1 tm2517509d2_ex4-1.htm EX-4.1 111747
3 EXHIBIT 5.1 tm2517509d2_ex5-1.htm EX-5.1 11191
4 EXHIBIT 10.1 tm2517509d2_ex10-1.htm EX-10.1 126159
5 EXHIBIT 99.1 tm2517509d2_ex99-1.htm EX-99.1 10686
9 GRAPHIC tm2517509d2_ex5-1img01.jpg GRAPHIC 3300
10 GRAPHIC tm2517509d2_ex5-1img02.jpg GRAPHIC 29256
11 GRAPHIC tm2517509d2_ex99-1img01.jpg GRAPHIC 3300
  Complete submission text file 0001104659-25-058888.txt   579550

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA rsls-20250608.xsd EX-101.SCH 3047
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE rsls-20250608_lab.xml EX-101.LAB 34239
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rsls-20250608_pre.xml EX-101.PRE 22380
21 EXTRACTED XBRL INSTANCE DOCUMENT tm2517509d2_8k_htm.xml XML 3572
Mailing Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673
Business Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673 949-429-6680
ReShape Lifesciences Inc. (Filer) CIK: 0001427570 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37897 | Film No.: 251042795
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)